Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
ANN ARBOR, MI—Warren Eric, the Chief Commercial Officer of Esperion Therapeutics, Inc. (NASDAQ:ESPR), a $367 million market cap pharmaceutical company that saw 187% revenue growth in the last twelve months, reported a sale of company stock according to a recent filing with the Securities and Exchange Commission. The transaction, which took place on February 19, involved the sale of 239 shares of common stock at a price of approximately $1.868 per share, totaling $446.
The shares were sold to cover tax obligations on vested restricted stock units, as noted in the filing. Following this transaction, Eric holds 159,759 shares directly. Esperion Therapeutics, headquartered in Ann Arbor, focuses on developing pharmaceutical preparations. According to InvestingPro, while the company isn’t currently profitable, analysts anticipate sales growth this year, with the next earnings report scheduled for February 27. Get deeper insights into insider trading patterns and 12+ more exclusive ProTips with an InvestingPro subscription.
In other recent news, Esperion Therapeutics has been active with several notable developments. The company reported a significant financial maneuver by issuing $100 million in 5.75% Convertible Senior Subordinated Notes due 2030. This transaction involved exchanging old notes and raising cash, aimed at strengthening its financial position. Esperion also provided an update on its expected operating expenses for 2025, projecting costs between $215 million and $235 million, which reflects a significant increase in spending.
On the clinical front, H.C. Wainwright maintained a Buy rating for Esperion, with a price target of $16, following positive findings from the CLEAR Outcomes Trial. The trial showed bempedoic acid’s clinical benefits for patients with high cardiovascular risk and obesity. Meanwhile, JMP Securities adjusted its price target to $4 but maintained a Market Outperform rating, citing consistent prescription growth for Esperion’s products, NEXLETOL and NEXLIZET.
Additionally, JMP Securities reiterated a $7 price target for Esperion, highlighting the efficacy and safety of NEXLETOL/NEXLIZET presented at a key opinion leader event. These developments indicate ongoing interest and analysis from financial firms, reflecting varying perspectives on the company’s potential and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.